Literature DB >> 23066093

The biarylpyrazole compound AM251 alters mitochondrial physiology via proteolytic degradation of ERRα.

Susan M Krzysik-Walker1, Isabel González-Mariscal, Morten Scheibye-Knudsen, Fred E Indig, Michel Bernier.   

Abstract

The orphan nuclear receptor estrogen-related receptor alpha (ERRα) directs the transcription of nuclear genes involved in energy homeostasis control and the regulation of mitochondrial mass and function. A crucial role for controlling ERRα-mediated target gene expression has been ascribed to the biarylpyrazole compound 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (AM251) through direct binding to and destabilization of ERRα protein. Here, we provide evidence that structurally related AM251 analogs also have negative impacts on ERRα protein levels in a cell-type-dependent manner while having no deleterious actions on ERRγ. We show that these off-target cellular effects of AM251 are mediated by proteasomal degradation of nuclear ERRα. Cell treatment with the nuclear export inhibitor leptomycin B did not prevent AM251-induced destabilization of ERRα protein, whereas proteasome inhibition with MG132 stabilized and maintained its DNA-binding function, indicative of ERRα being a target of nuclear proteasomal complexes. NativePAGE analysis revealed that ERRα formed a ∼220-kDa multiprotein nuclear complex that was devoid of ERRγ and the coregulator peroxisome proliferator-activated receptor γ coactivator-1. AM251 induced SUMO-2,3 incorporation in ERRα in conjunction with increased protein kinase C activity, whose activation by phorbol ester also promoted ERRα protein loss. Down-regulation of ERRα by AM251 or small interfering RNA led to increased mitochondria biogenesis while negatively impacting mitochondrial membrane potential. These results reveal a novel molecular mechanism by which AM251 and related compounds alter mitochondrial physiology through destabilization of ERRα.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23066093      PMCID: PMC3533472          DOI: 10.1124/mol.112.082651

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  46 in total

1.  AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Authors:  Kathryn A Seely; Lisa K Brents; Lirit N Franks; Maheswari Rajasekaran; Sarah M Zimmerman; William E Fantegrossi; Paul L Prather
Journal:  Neuropharmacology       Date:  2012-07-04       Impact factor: 5.250

Review 2.  CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).

Authors:  R B Raffa; S J Ward
Journal:  J Clin Pharm Ther       Date:  2011-07-11       Impact factor: 2.512

Review 3.  Crosstalk between mitochondrial (dys)function and mitochondrial abundance.

Authors:  Sébastien Michel; Anaïs Wanet; Aurélia De Pauw; Guillaume Rommelaere; Thierry Arnould; Patricia Renard
Journal:  J Cell Physiol       Date:  2012-06       Impact factor: 6.384

4.  SUMOylation of Blimp-1 promotes its proteasomal degradation.

Authors:  Livnat Shimshon; Avital Michaeli; Rivka Hadar; Stephen L Nutt; Yael David; Ami Navon; Ari Waisman; Boaz Tirosh
Journal:  FEBS Lett       Date:  2011-06-25       Impact factor: 4.124

5.  The cannabinoid receptor inverse agonist AM251 regulates the expression of the EGF receptor and its ligands via destabilization of oestrogen-related receptor α protein.

Authors:  J L Fiori; M Sanghvi; M P O'Connell; S M Krzysik-Walker; R Moaddel; M Bernier
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Competition between sumoylation and ubiquitination of serine hydroxymethyltransferase 1 determines its nuclear localization and its accumulation in the nucleus.

Authors:  Donald D Anderson; Jae Y Eom; Patrick J Stover
Journal:  J Biol Chem       Date:  2011-12-21       Impact factor: 5.157

7.  3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.

Authors:  Jenny L Wiley; Dana E Selley; Pinglang Wang; Rudresha Kottani; Srinivas Gadthula; Anu Mahadeven
Journal:  J Pharmacol Exp Ther       Date:  2011-11-15       Impact factor: 4.030

8.  The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.

Authors:  R Baur; J Gertsch; E Sigel
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

9.  Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet.

Authors:  Mélissa Flamment; Naïg Gueguen; Céline Wetterwald; Gilles Simard; Yves Malthièry; Pierre-Henri Ducluzeau
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-09-01       Impact factor: 4.310

10.  The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity.

Authors:  José María Moreno-Navarrete; Victoria Catalán; Lauren Whyte; Adenis Díaz-Arteaga; Rafael Vázquez-Martínez; Fernando Rotellar; Rocío Guzmán; Javier Gómez-Ambrosi; Marina R Pulido; Wendy R Russell; Mónica Imbernón; Ruth A Ross; María M Malagón; Carlos Dieguez; José Manuel Fernández-Real; Gema Frühbeck; Ruben Nogueiras
Journal:  Diabetes       Date:  2011-12-16       Impact factor: 9.461

View more
  5 in total

Review 1.  Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer.

Authors:  Felicity Eb May
Journal:  Cancer Manag Res       Date:  2014-05-23       Impact factor: 3.989

2.  The Combination of Δ9-Tetrahydrocannabinol and Cannabidiol Suppresses Mitochondrial Respiration of Human Glioblastoma Cells via Downregulation of Specific Respiratory Chain Proteins.

Authors:  Anne Rupprecht; Ulrike Theisen; Franziska Wendt; Marcus Frank; Burkhard Hinz
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

3.  The estrogen-related receptor α inverse agonist XCT 790 is a nanomolar mitochondrial uncoupler.

Authors:  Banu Eskiocak; Aktar Ali; Michael A White
Journal:  Biochemistry       Date:  2014-07-14       Impact factor: 3.162

4.  Modulation of estrogen related receptor alpha activity by the kinesin KIF17.

Authors:  Am Pramodh Bandara Seneviratne; Zeynep Turan; Aurelie Hermant; Patrick Lecine; William O Smith; Jean-Paul Borg; Fanny Jaulin; Geri Kreitzer
Journal:  Oncotarget       Date:  2017-05-23

5.  Oestrogen-related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1.

Authors:  Yantao Chen; Kunshui Zhang; Yang Li; Ruilian Guo; Kelin Zhang; Guifang Zhong; Qing He
Journal:  J Cell Mol Med       Date:  2019-01-04       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.